An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT06047080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Study identification
- NCT ID
- NCT06047080
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,130 participants
Conditions and interventions
Conditions
Interventions
- Glofitamab Drug
- Polatuzumab vedotin Drug
- Rituximab Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 17, 2023
- Primary completion
- Sep 30, 2027
- Completion
- Oct 29, 2030
- Last update posted
- Jun 14, 2026
2023 – 2030
United States locations
- U.S. sites
- 60
- U.S. states
- 28
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology & Hematology, LLC | Anchorage | Alaska | 99508 | — |
| Kaiser Permanente - Anaheim (E. La Palma) | Anaheim | California | 92806 | — |
| University of California, San Francisco-Fresno | Clovis | California | 93611 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| City of Hope - Lennar Foundation Cancer Center | Irvine | California | 92618 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| UCLA Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
| Kaiser Permanente - Roseville | Roseville | California | 95661 | — |
| Kaiser Permanente - Santa Clara | Santa Clara | California | 95051 | — |
| Stanford Univ School of Med | Stanford | California | 94305-5821 | — |
| Kaiser Permanente Medical Ctr | Vallejo | California | 94589 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Center - Denver | Littleton | Colorado | 80120 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06519 | — |
| Medstar Franklin Square Medical Center | Washington D.C. | District of Columbia | 20010 | — |
| Miami Cancer Institute of Baptist Health, Inc. | Miami | Florida | 33176 | — |
| Memorial Cancer Institute at Memorial West | Pembroke Pines | Florida | 33028 | — |
| Hawaii Cancer Care | Honolulu | Hawaii | 96813 | — |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois | 60637-1447 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| Springfield Clinic | Springfield | Illinois | 62702 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Ascension Via Christi Research | Wichita | Kansas | 67214 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Boston Medical Center | Boston | Massachusetts | 02218 | — |
| Henry Ford Health System | Novi | Michigan | 48377-3600 | — |
| M Health Fairview University of Minnesota Medical Center | Minneapolis | Minnesota | 55455 | — |
| St. Luke's Hospital | Chesterfield | Missouri | 63017 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-0600 | — |
| NYU Langone Hospital?Brooklyn | Brooklyn | New York | 11220 | — |
| NYU Long Island Hospital | Mineola | New York | 11501 | — |
| New York University Medical Center PRIME | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care | New York | New York | 10021 | — |
| Weill Cornell Medical College-New York Presbyterian Hospital | New York | New York | 10021 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| North Shore Hematology Oncology Association PC | Shirley | New York | 11967 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| New York Cancer & Blood Specialists | The Bronx | New York | 10469 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Willamette Valley Cancer Insitute and Research Center | Springfield | Oregon | 97477 | — |
| Kimmel Cancer Center Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Greco-Hainesworth Tennessee Oncology Centers for Research | Chattanooga | Tennessee | 37404 | — |
| West Cancer Center & Research Institute | Germantown | Tennessee | 38138 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| USOR - Texas Oncology - San Antonio Northeast | San Antonio | Texas | 78217 | — |
| University of Vermont | Burlington | Vermont | 05401 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Newport News | Virginia | 23606 | — |
| Swedish Medical Center | Seattle | Washington | 98104-1360 | — |
| University of Washington - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
| Univ of Wisconsin Hosp & Clin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 169 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06047080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06047080 live on ClinicalTrials.gov.